Oppenheimer initiated coverage of Gossamer Bio with an Outperform rating and $9 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Biotech Alert: Searches spiking for these stocks today
- Aerovate Therapeutics downgraded to Neutral from Buy at Guggenheim
- Gossamer Bio rises following competitorâs failure in PAH trial
- Goldman says PAH opportunity now incrementally more attractive for Gossamer Bio
- Gossamer Bio reports Q1 EPS (19c), consensus (19c)